Arctic Therapeutics secures funding to fast-track dementia and skin disease treatments
Arctic Therapeutics (ATx) has secured fresh investment to push forward two promising drugs. The company uses a novel approach, blending bioinformatics and genomics to tackle diseases at their source. Their latest funding will speed up research into treatments for dementia and inflammatory skin conditions.
ATx focuses on the genetic and protein roots of diseases. By pinpointing key targets, the company aims to cut the time, cost, and risks of drug development. Their method has already drawn attention from investors, including the European Commission's EIC Fund.
The first drug, AT-001, targets a rare form of familial dementia caused by harmful protein buildup. Taken as a pill, it works by breaking down and clearing amyloid clusters in the brain. The European Medicines Agency (EMA) recently approved a clinical trial to test its effects. If successful, ATx believes the treatment could slow dementia progression, delay its onset, or even reverse symptoms.
Meanwhile, AT-004 is set for trials in acne treatment, with plans to expand into other inflammatory skin diseases. The new funding will help accelerate both programmes, moving them closer to potential approval.
The Series A investment will allow ATx to advance its two lead drugs through clinical testing. AT-001's trial for dementia marks a key step, while AT-004 could soon enter studies for skin conditions. The company's approach—targeting disease mechanisms directly—could reshape how future treatments are developed.
